Top-News
Biotechnologie USA

Immunic Inc Aktie

Aktie
WKN:  A2PHD4 ISIN:  US4525EP1011 US-Symbol:  IMUX
1,016 €
+0,005 €
+0,49%
13.01.25
Handeln Depot/Watchlist
Aktienanzahl *
90,08 Mio.
Marktkapitalisierung *
108,86 Mio. €
Streubesitz
68,06%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 19.08.2024

Immunic Inc News

07.01.25 - EQS
EQS-News: Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Issuer: Immunic AG / Key word(s): Miscellaneous Immunic Highlights 2024 Accomplishments and Upcoming Milestones 07.01.2025 / 12:30 CET/CEST The issuer is solely ...
07.01.25 - PR Newswire
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Immunic Highlights 2024 Accomplishments and Upcoming Milestones PR Newswire
26.11.24 - PR Newswire
Immunic, Inc. to Participate in Investor Conference in December
Immunic, Inc. to Participate in Investor Conference in December PR Newswire
13.11.24 - EQS
EQS-News: Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
Issuer: Immunic AG / Key word(s): Scientific publication Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet ...
13.11.24 - PR Newswire
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology PR Newswire
07.11.24 - EQS
EQS-News: Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Issuer: Immunic AG / Key word(s): Quarter Results Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update 07.11.2024 / 12:30 CET/CEST The ...
07.11.24 - PR Newswire
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR Newswire
31.10.24 - EQS
EQS-News: Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
Issuer: Immunic AG / Key word(s): Miscellaneous Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update ...
31.10.24 - PR Newswire
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update PR Newswire
29.10.24 - EQS
EQS-News: Immunic to Participate in Industry, Scientific and Investor Conferences in November
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Industry, Scientific and Investor Conferences in November 29.10.2024 / 11:30 CET/CEST The issuer is ...
29.10.24 - PR Newswire
Immunic to Participate in Industry, Scientific and Investor Conferences in November
Immunic to Participate in Industry, Scientific and Investor Conferences in November PR Newswire
22.10.24 - 4investors
Immunic: „Meilenstein für das Programm”
22.10.24 - EQS
EQS-News: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
Issuer: Immunic AG / Key word(s): Study results Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing ...
22.10.24 - PR Newswire
Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis PR Newswire
18.09.24 - EQS
EQS-News: Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
Issuer: Immunic AG / Key word(s): Conference Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in ...
18.09.24 - PR Newswire
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis PR Newswire
04.09.24 - 4investors
Immunic: Studie untersucht Vidofludimus Calcium bei Post-COVID-Syndrom
04.09.24 - EQS
EQS-News: Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
Issuer: Immunic AG / Key word(s): Study Immunic Announces First Patient Enrolled in Investigator-​Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post ...
04.09.24 - PR Newswire
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
Immunic Announces First Patient Enrolled in Investigator-​Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome PR Newswire
28.08.24 - EQS
EQS-News: Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
Issuer: Immunic AG / Key word(s): Conference Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September 28.08.2024 / 12:30 ...

Newssuche

Videos

newspaper
13.01.25 +4,96%
Technical Trading: Cotton Zukauf Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »